Abstract:Abstract Background Multiple sclerosis (MS) and neuromyelitis optica syndrome disease (NMOSD) are inflammatory diseases of the central nervous system. The pathogenesis and treatments for these two conditions are very different. Natural killer (NK) and natural killer T (NKT) cells are immune cells with an important role in shaping the immune response. B cells are involved in antigen presentation as well as antibody and cytokine production. There is conflicting evidence of the roles of NK, NKT, and B cells in the two conditions. We aimed to compare the frequency of CD3 − CD16 + CD56 + NK, CD3 + CD56 + NKT, and CD5 + CD19 + B cells in the peripheral blood and serum Interleukin-10 (IL-10) in patients with MS and NMOSD. Methods CD19 + CD5 + B, CD3 − CD16 + CD56 + NK, and CD3 + CD56 + NKT cells were quantitated by flow cytometry in 15 individuals with Interferon-Beta (IFN-β) treated relapsing–remitting MS (RRMS), 15 untreated RRMS, and 15 NMOSD patients as well as 30 healthy controls (HC). Serum IL-10 was measured using an enzyme-linked immunosorbent assay (ELISA). Results The percentage of CD3 − CD56 + CD16 + NK cells in the peripheral blood of IFN-treated MS (1.81 ± 0.87) was significantly lower than for untreated RRMS (4.74 ± 1.80), NMOSD (4.64 ± 1.26) and HC (5.83 ± 2.19) (p < 0.0001). There were also differences for the percentage of CD3 − CD16 + and CD3 − CD56 + cells (p < 0.001 and p < 0.0007; respectively). IFN-treated RRMS (2.89 ± 1.51) had the lowest proportion of CD3 + CD56 + among the study groups (p < 0.002). Untreated RRMS (5.56 ± 3.04) and NMOSD (5.47 ± 1.24) had higher levels of CD3 + CD56 + than the HC (3.16 ± 1.98). The mean percentage of CD19 + CD5 + B cells in the peripheral blood of untreated RRMS patients (1.32 ± 0.67) was higher compared to the patients with NMOSD (0.30 ± 0.20), HC (0.5 ± 0.22) and IFN-treated RRMS (0.81 ± 0.17) (p < 0.0001). Serum interleukin-10 was significantly higher in the IFN-treated RRMS (8.06 ± 5.39) and in HC (8.38 ± 2.84) compared to untreated RRMS (5.07 ± 1.44) and the patients with NMOSD (5.33 ± 2.56) (p < 0.003). Conclusions The lower proportion of CD3 − CD56 + CD16 + NK and CD3 + CD56 + cells in peripheral blood of IFN-treated RRMS compared to other groups suggests the importance of immunomodulation in patients with RRMS disorder. Based on the differences in CD19 + CD5 + B cells and serum IL-10 between patients and HC, supplementary assessments could be of value in clarifying their roles in autoimmunity.

The frequencies of peripheral blood CD5+CD19+ B cells, CD3−CD16+CD56+ NK, and CD3+CD56+ NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder

Decreased Serum IL-22 Levels in Patients with Systemic Lupus Erythematosus

The Differential Expression of Natural Killer Cells in NMOSD and MS

Neuromyelitis optica (NMO) and Multiple sclerosis (MS) are two typical inflammatory demyelinating diseases of the central nervous system (CNS) with complex pathogenesis, and they share many similarities. Neuromyelitis optica was considered an optic-spinal form of MS until specific antibodies (NMO-Ig

Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder.

Serum Immunoglobulin G Level and Neutrophils to Lymphocytes Ratio Associated with the Prognosis of Neuromyelitis Optica Spectrum Disorder.

Th2 Axis-Related Cytokines in Patients with Neuromyelitis Optica Spectrum Disorders

Changes in circulating follicular helper T cells and regulatory follicular T cells in patients with neuromyelitis optica spectrum disorder

Association of Circulating Follicular Helper T Cells with Disease Course of NMO Spectrum Disorders.

Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation

Lower Serum Interleukin-22 and Interleukin-35 Levels Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders.

Association of Circulating Follicular Helper T Cells and Serum CXCL13 With Neuromyelitis Optica Spectrum Disorders

A-100 Selected pro-and anti-inflammatory cytokine serum concentrations in different clinical forms of multiple sclerosis

Cerebrospinal Fluid IL-21 Levels in Neuromyelitis Optica and Multiple Sclerosis

Impaired Regulatory Function and Enhanced Intrathecal Activation of B Cells in Neuromyelitis Optica: Distinct from Multiple Sclerosis

Interleukin-17-secreting T Cells in Neuromyelitis Optica and Multiple Sclerosis During Relapse

[Different Responses of CD94/NKG2A-bright and CD94/NKG2A-dim NK Cell Subsets Isolated from Patients with Multiple Sclerosis to Interferon-Beta].

The Study on Secretion of Cytokine Interleukin-4, Interleukin-10 and Interferon-Γ in Peripheral Blood of Multiple Sclerosis Patients

The Ratio of Circulating CD56dim NK Cells to Follicular T Helper Cells As a Promising Predictor for Disease Activity of Relapsing-Remitting Multiple Sclerosis

Interleukin-36 Alpha Levels Are Elevated in the Serum and Cerebrospinal Fluid of Patients with Neuromyelitis Optica Spectrum Disorder and Correlate with Disease Activity

Association of Circulating T Follicular Helper Cells With Idiopathic Optic Neuritis and Neuromyelitis Optica Spectrum Disorders